LIFECORE BIOMEDICAL, INC. Increase (Decrease) in Restricted Cash for Operating Activities
LIFECORE BIOMEDICAL, INC. (LFCR) reported Increase (Decrease) in Restricted Cash for Operating Activities of $100.00 thousand for the 9-month period ending 2017-02-26, per its 10-Q filed 2018-04-05.
Discontinued › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInRestrictedCashForOperatingActivities · last filed 2018-04-05
- 2017-02-26: Increase (Decrease) in Restricted Cash for Operating Activities 9 month $100.00K.
- 2016-02-28: Increase (Decrease) in Restricted Cash for Operating Activities 9 month $225.00K.
| Period end | Increase (Decrease) in Restricted Cash for Operating Activities 9 month |
|---|---|
| 2017-02-26 | $100.00K 10-Q · filed 2018-04-05 |
| 2016-02-28 | $225.00K 10-Q · filed 2017-04-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ADC Therapeutics SA (ADCT) | $0.163B | -1.39 | |
| Minerva Neurosciences, Inc. (NERV) | United States | $0.165B | -0.66 |
| Tonix Pharmaceuticals Holding Corp. (TNXP) | United States | $0.166B | -1.34 |
| Annexon, Inc. (ANNX) | United States | $0.147B | -4.22 |
| Corbus Pharmaceuticals Holdings, Inc. (CRBP) | United States | $0.144B | -1.72 |
| Organogenesis Holdings Inc. (ORGO) | United States | $0.182B | -3.70 |
| SPRUCE BIOSCIENCES, INC. (SPRB) | United States | $0.142B | -2.89 |
| Korro Bio, Inc. (KRRO) | United States | $0.141B | -1.81 |
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| Atrium Therapeutics, Inc. (RNA) | United States | $0.140B |